The expansive, all-in-one guide to
successful pharmaceutical project management
To improve the ways they currently manage projects and programs, pharmaceutical and biotechnology companies need reliable stewardship to direct future strategies. Unlike other industry sectors, they have yet to fully embrace the effective integrated processes of Portfolio, Program, and Project Management, otherwise referred to as P3M, to position themselves favorably in meeting challenges unique to the drug development business.
Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries illustrates how high-quality program and project management is crucial for drug companies to remain competitive, to deliver good returns to investors, and ultimately to bring novel personalized medicine to patients with:
* A combination of theoretical insights and pragmatic examples from professionals who are all working in the industry
* Case studies with very detailed, real-life examples of how the management of drug development is actually done
* Answers the pharmaceutical industry needs to streamline and make the drug development process more efficient
* The full spectrum of management processes needed from the operational-ization of corporate strategy by portfolio management processes through to practical project control processes
Carefully divided into three main sections to cover topics such as the impact of organizational size on P3M; planning and control; and reducing product safety risk, this informative reference is structured to align both novices and professionals in drug program management with success in the wake of emerging trends.
Über den Autor und weitere Mitwirkende
Pete Harpum is a Director of Harpum Consulting and has been consulting on Portfolio, Program, and Project Management (P3M) for some ten years. He chairs and contributes to many conferences and symposiums on P3M. Mr. Harpum's other activities include postgraduate lecturing and research on P3M for three world-class universities, and supporting the Association for Project Management, Project Management Institute, and the Drug Information Association in various ways.